Christina L Roland1, Matthew H G Katz2, Ching-Wei D Tzeng2,3, Heather Lin4, Gauri R Varadhachary5, Rachna Shroff5, Milind Javle5, David Fogelman5, Robert A Wolff5, Jean N Vauthey2, Christopher H Crane6, Jeffrey E Lee2, Jason B Fleming2. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. clroland@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Surgery, University of Kentucky, Lexington, KY, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: Preoperative/neoadjuvant therapy (NT) is increasingly utilized for the treatment of pancreatic ductal adenocarcinoma (PDAC). However, little data exist regarding information on the use of additional postoperative therapy following NT. The lymph node ratio (LNR) is a prognostic marker of oncologic outcomes after NT and resection. In this study, we evaluated the effectiveness of postoperative therapy following NT, stratified by LNR. METHODS: A prospective tumor registry database was queried to identify patients with PDAC who underwent resection following NT from 1990 to 2008. Clinicopathologic factors were compared to identify associations with overall survival (OS) and time to recurrence (TTR) based on postoperative chemotherapy status. RESULTS: Thirty-six (14 %) of the 263 patients received additional postoperative therapy. No differences were observed in the pathologic characteristics between patients who received postoperative chemotherapy and those who did not. The median LNR was 0.12 for patients with N + disease. Following NT, the administration of postoperative therapy was associated with improved median OS (72 vs. 33 months; p = 0.008) for patients with an LNR < 0.15. There was no association between postoperative chemotherapy and OS for patients with LNR ≥ 0.15. Multivariate analysis demonstrated that the administration of postoperative systemic therapy in patients with a low LNR was associated with a reduced risk of death (hazard ratio 0.49; p = 0.02). CONCLUSION: Postoperative chemotherapy after NT in patients with low LNR is associated with improved oncologic outcomes.
BACKGROUND: Preoperative/neoadjuvant therapy (NT) is increasingly utilized for the treatment of pancreatic ductal adenocarcinoma (PDAC). However, little data exist regarding information on the use of additional postoperative therapy following NT. The lymph node ratio (LNR) is a prognostic marker of oncologic outcomes after NT and resection. In this study, we evaluated the effectiveness of postoperative therapy following NT, stratified by LNR. METHODS: A prospective tumor registry database was queried to identify patients with PDAC who underwent resection following NT from 1990 to 2008. Clinicopathologic factors were compared to identify associations with overall survival (OS) and time to recurrence (TTR) based on postoperative chemotherapy status. RESULTS: Thirty-six (14 %) of the 263 patients received additional postoperative therapy. No differences were observed in the pathologic characteristics between patients who received postoperative chemotherapy and those who did not. The median LNR was 0.12 for patients with N + disease. Following NT, the administration of postoperative therapy was associated with improved median OS (72 vs. 33 months; p = 0.008) for patients with an LNR < 0.15. There was no association between postoperative chemotherapy and OS for patients with LNR ≥ 0.15. Multivariate analysis demonstrated that the administration of postoperative systemic therapy in patients with a low LNR was associated with a reduced risk of death (hazard ratio 0.49; p = 0.02). CONCLUSION: Postoperative chemotherapy after NT in patients with low LNR is associated with improved oncologic outcomes.
Authors: Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang Journal: Cancer Date: 2011-07-06 Impact factor: 6.860
Authors: Lauren E Colbert; William A Hall; Dana Nickleach; Jeffrey Switchenko; David A Kooby; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; John Kauh; Jerome C Landry Journal: Cancer Date: 2014-01-03 Impact factor: 6.860
Authors: Christina L Roland; Anthony D Yang; Matthew H G Katz; Deyali Chatterjee; Huamin Wang; Heather Lin; Jean N Vauthey; Peter W Pisters; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Jeffrey E Lee; Jason B Fleming Journal: Ann Surg Oncol Date: 2014-10-29 Impact factor: 5.344
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: R R White; H I Hurwitz; M A Morse; C Lee; M S Anscher; E K Paulson; M R Gottfried; J Baillie; M S Branch; P S Jowell; K M McGrath; B M Clary; T N Pappas; D S Tyler Journal: Ann Surg Oncol Date: 2001-12 Impact factor: 5.344
Authors: Ching-Wei D Tzeng; Jason B Fleming; Jeffrey E Lee; Lianchun Xiao; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert A Wolff; Gauri R Varadhachary; David R Fogelman; Christopher H Crane; Aparna Balachandran; Matthew H G Katz Journal: Ann Surg Oncol Date: 2012-01-19 Impact factor: 5.344
Authors: Mark B Slidell; David C Chang; John L Cameron; Christopher Wolfgang; Joseph M Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2007-09-26 Impact factor: 5.344
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; James S Tomlinson; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Cancer Date: 2007-09-15 Impact factor: 6.860
Authors: Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Rosa F Hwang; Huamin Wang; Axbal Lara; Henry Gomez; Tracy Chang; Nicole Sieffert; Younghee Moon; Sabina Ram; Stuart Zimmerman; Jeffrey H Lee; Peter W T Pisters; Eric P Tamm; Jason B Fleming; James L Abbruzzese; Douglas B Evans Journal: Ann Surg Oncol Date: 2008-02-07 Impact factor: 5.344
Authors: Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: J Gastrointest Surg Date: 2017-08-28 Impact factor: 3.452
Authors: Susanna W L de Geus; Gyulnara G Kasumova; Mariam F Eskander; Sing Chau Ng; Tara S Kent; A James Moser; Alexander L Vahrmeijer; Mark P Callery; Jennifer F Tseng Journal: J Gastrointest Surg Date: 2017-10-04 Impact factor: 3.452
Authors: Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee Journal: J Gastrointest Surg Date: 2016-10-24 Impact factor: 3.452
Authors: Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: Jaewoo Park; Hae Young Kim; Hee Young Na; Jun Suh Lee; Jong-Chan Lee; Jin Won Kim; Yoo-Seok Yoon; Jin-Hyeok Hwang; Ho-Seong Han; Jaihwan Kim Journal: J Cancer Res Clin Oncol Date: 2022-06-20 Impact factor: 4.553
Authors: Sung Jun Ma; Lucas M Serra; Austin J Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J Iovoli; Gregory M Hermann; Han Yu; Anurag K Singh Journal: J Radiother Pract Date: 2021-04-14
Authors: Dany Barrak; Anthony M Villano; Nicole Villafane-Ferriol; Leah G Stockton; Maureen V Hill; Mengying Deng; Elizabeth A Handorf; Sanjay S Reddy Journal: Eur J Surg Oncol Date: 2022-01-05 Impact factor: 4.037
Authors: Douglas S Swords; Samual R Francis; Shane Lloyd; Ignacio Garrido-Laguna; Sean J Mulvihill; Joshua D Gruhl; Miles C Christensen; Gregory J Stoddard; Matthew A Firpo; Courtney L Scaife Journal: J Gastrointest Surg Date: 2018-09-05 Impact factor: 3.452